Sunpharma Ltd — Q2 FY24
Sun Pharma reported Q2 FY24 consolidated revenue of INR 12,003 crore, up 11% YoY, driven by India formulations (11.1% growth) and global specialty sales (19.3% growth to $240M).
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY24
R&D spend guidance maintained at ~6-7% of sales for FY24
Management reiterated full-year R&D guidance, with potential updates if needed. Concert Pharma costs are included.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY24
India business to grow in line with or better than market in coming quarters
CEO Kirti Ganorkar expressed confidence that India formulation growth will align with IPM growth, recovering from NLEM and sitagliptin impacts.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY24
Lenalidomide sales expected to remain episodic
CFO noted that lenalidomide sales were significant in Q1 but will be episodic going forward, not a steady revenue stream.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1